Randomised phase II study with cetuximab (Erbitux) in combination with 5-FU and cisplatin or carboplatin versus cetuximab (Erbitux) in combination with paclitaxel and carboplatin for treatment of patients with relapsed or metastatic squamous cell carcinoma of the head and neck.
Latest Information Update: 05 May 2021
At a glance
- Drugs Cetuximab (Primary) ; Carboplatin; Cisplatin; Fluorouracil; Paclitaxel
- Indications Head and neck cancer; Squamous cell cancer
- Focus Therapeutic Use
- Acronyms CETMET
- 05 May 2021 This trial has been completed in Sweden, according to European Clinical Trials Database record.
- 07 Sep 2020 This trial has been completed in Denmark, according to European Clinical Trials Database record.
- 05 Jun 2018 Results evaluating efficacy and safety of cetuximab (n=85) were presented at the 54th Annual Meeting of the American Society of Clinical Oncology